Details of the Drug Combination

General Information of Drug Combination (ID: DC2OKH4)

• Drug Combination Name: ABIRATERONE + Picoplatin
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  ABIRATERONE (DM8V75C): Small molecular drug
  Picoplatin (DM0PIY6): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: DU-145
  Zero Interaction Potency (ZIP) Score: 2.54
  Bliss Independence Score: 5.41
  Loewe Additivity Score: 4.46
  LHighest Single Agent (HSA) Score: 1.37

Molecular Interaction Atlas of This Drug Combination

Indication(s) of ABIRATERONE

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[2]

ABIRATERONE Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Steroid 17-alpha-monooxygenase (S17AH)	TTRA5BZ	CP17A_HUMAN	Modulator	[4]

Indication(s) of Picoplatin

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[3]
Ovarian cancer	2C73	Phase 3	[3]
Prostate cancer	2C82.0	Phase 3	[3]
Small-cell lung cancer	2C25.Y	Phase 3	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Renal cell carcinoma	DC61VMN	UO-31	Investigative	[5]
Minimally invasive lung adenocarcinoma	DC1KMSQ	NCI-H322M	Investigative	[1]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
• [3] ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
• [4] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [5] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966